1. Home
  2. ACRS vs FSP Comparison

ACRS vs FSP Comparison

Compare ACRS & FSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • FSP
  • Stock Information
  • Founded
  • ACRS 2012
  • FSP 1981
  • Country
  • ACRS United States
  • FSP United States
  • Employees
  • ACRS N/A
  • FSP N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • FSP Real Estate Investment Trusts
  • Sector
  • ACRS Health Care
  • FSP Real Estate
  • Exchange
  • ACRS Nasdaq
  • FSP Nasdaq
  • Market Cap
  • ACRS 165.7M
  • FSP 166.9M
  • IPO Year
  • ACRS 2015
  • FSP N/A
  • Fundamental
  • Price
  • ACRS $1.80
  • FSP $1.70
  • Analyst Decision
  • ACRS Strong Buy
  • FSP
  • Analyst Count
  • ACRS 9
  • FSP 0
  • Target Price
  • ACRS $9.25
  • FSP N/A
  • AVG Volume (30 Days)
  • ACRS 1.4M
  • FSP 330.5K
  • Earning Date
  • ACRS 08-07-2025
  • FSP 07-29-2025
  • Dividend Yield
  • ACRS N/A
  • FSP 2.47%
  • EPS Growth
  • ACRS N/A
  • FSP N/A
  • EPS
  • ACRS N/A
  • FSP N/A
  • Revenue
  • ACRS $16,789,000.00
  • FSP $111,879,000.00
  • Revenue This Year
  • ACRS N/A
  • FSP $4.36
  • Revenue Next Year
  • ACRS $8.11
  • FSP $0.81
  • P/E Ratio
  • ACRS N/A
  • FSP N/A
  • Revenue Growth
  • ACRS N/A
  • FSP N/A
  • 52 Week Low
  • ACRS $1.05
  • FSP $1.36
  • 52 Week High
  • ACRS $5.17
  • FSP $2.21
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 62.45
  • FSP 56.64
  • Support Level
  • ACRS $1.75
  • FSP $1.60
  • Resistance Level
  • ACRS $1.92
  • FSP $1.70
  • Average True Range (ATR)
  • ACRS 0.09
  • FSP 0.06
  • MACD
  • ACRS 0.01
  • FSP 0.01
  • Stochastic Oscillator
  • ACRS 70.00
  • FSP 85.71

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.

Share on Social Networks: